The German-made BioNTech jabs appear to work better than the Chinese-manufactured Sinovac vaccine among people who have received either one or two doses.
The case fatality rate for people who had received one dose of the BioNTech vaccine was 0.21 per cent, and it was further lowered to 0.04 per cent among people who were double vaccinated, according to government data.
Among the Sinovac recipients, the figure was 1.28 per cent for people who had received one dose, and 0.31 per cent for those who got two jabs.
The fatality rate for the third dose of Sinovac and BioNTech vaccines was 0.04 per cent and 0.02 per cent, respectively.